

## **INDEPENDENT AUDITOR'S REPORT**

To the Members of Saket City Hospitals Private Limited

### **Report on the Ind AS Financial Statements**

We have audited the accompanying Ind AS financial statements of Saket City Hospitals Private Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of the Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act., read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Ind AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

## **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2017, its loss including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

## **Emphasis of Matter**

We draw attention to Note XX in the financial statements which, indicate that the Company has accumulated losses and its net worth has been fully eroded, the Company has incurred a net loss/net cash loss during the current and previous year(s). These conditions, along with other matters set forth in Note XX, indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Our opinion is not qualified in respect of this matter.

## **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143 (3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - (c) The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
  - (d) In our opinion, the aforesaid Ind AS financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 Companies (Indian Accounting Standards) Rules, 2015, as amended;
  - (e) On the basis of written representations received from the directors as on March 31, 2017, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017, from being appointed as a director in terms of section 164 (2) of the Act;
  - (f) The going concern matter described under the Emphasis of Matters paragraph above, in our opinion, may have an adverse effect on the functioning of the Company;
  - (g) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;
  - (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company has disclosed the impact of pending litigations on its financial position in its Ind AS financial statements – Refer Note XX to the Ind AS financial statements;
- ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts – Refer Note XX to the Ind AS financial statements;
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company;
- iv. The Company has provided requisite disclosures in Note XXX to the Ind AS financial statements as to the holding of Specified Bank Notes on November 8, 2016 and December 30, 2016 as well as dealings in Specified Bank Notes during the period from November 8, 2016 to December 30, 2016. Based on our audit procedures and relying on the management representation regarding the holding and nature of cash transactions, including Specified Bank Notes, we report that these disclosures are in accordance with the books of accounts maintained by the Company and as produced to us by the Management.

**For S.R. BATLIBOI & CO LLP**  
**ICAI Firm registration number: 301003E / E300005**  
Chartered Accountants

**Sd/-**  
**per Atul Seksaria**  
Partner  
Membership No.: 86370

Place: Gurgaon  
Date: May 17, 2017

**Annexure referred to in paragraph 1 under the heading “Report on other legal and regulatory requirements” of our report of even date**

**Re: Saket City Hospitals Private Limited (the Company)**

- (i)(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (b) According to the information and explanations given by the management, the title deeds of immovable properties included in property, plant and equipment are held in the name of the company.
- (ii)(a) The Company’s business does not involve inventories and, accordingly, the requirements under paragraph 3(ii) of the Order are not applicable to the Company.
- (iii)(a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.
- (iv) In our opinion and according to the information and explanations given to us, there are no loans, investments, guarantees, and securities given in respect of which provisions of section 185 and 186 of the Companies Act 2013 are applicable and hence not commented upon.
- (v) The Company has not accepted any deposits from the public.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the healthcare services, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii)(a) The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees’ state insurance, income-tax, sales-tax, service tax, customs duty, excise duty, value added tax, cess and other material statutory dues applicable to it.
- (b) According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees’ state insurance, income-tax, service tax, sales-tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.
- (c) According to the information and explanations given to us, there are no dues of income tax, sales-tax, service tax, customs duty, excise duty, value added tax and cess which have not been deposited on account of any dispute.
- (viii) In our opinion and according to the information and explanations given by the management, we are of the opinion that the Company has not defaulted in repayment of dues to banks. The Company did not have any outstanding dues in respect of a financial institution or debenture holders or government.
- (ix) In our opinion and according to the information and explanations given by the management, the Company has utilized the monies raised by way of term loans for the purpose for which they were raised. The Company has not raised any money by way of initial public offer / further public offer /debt instruments.

- (x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the company or no material fraud on the company by the officers and employees of the Company has been noticed or reported during the year.
- (xi) According to the information and explanations given by the management, the provisions of section 197 read with Schedule V of the Act are not applicable to the company and hence reporting under clause 3(xi) are not applicable and hence not commented upon.
- (xii) In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.
- (xiii) According to the information and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- (xiv) According to the information and explanations given by the management, the Company has complied with provisions of section 42 of the Companies Act, 2013 in respect of the preferential allotment or private placement of shares/ fully or partly convertible debentures during the year. According to the information and explanations given by the management, we report that the amounts raised, have been used for the purposes for which the funds were raised.
- (xv) According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of Companies Act, 2013.
- (xvi) According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

For **S.R. Batliboi & CO. LLP**  
Chartered Accountants  
ICAI Firm Registration Number: 301003E/E300005

**Sd/-**  
**per Atul Seksaria**  
Partner  
Membership Number: 86370

Place: Gurgaon  
Date: May 17, 2017

## **ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF SAKET CITY HOSPITALS PRIVATE LIMITED**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

To the Members of Saket City Hospitals Private Limited

We have audited the internal financial controls over financial reporting of Saket City Hospitals Private Limited ("the Company") as of March 31, 2017 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the

transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For S.R. BATLIBOI & CO LLP**

**ICAI Firm registration number: 301003E / E300005**

Chartered Accountants

**Sd/-**

**per Atul Seksaria**

Partner

Membership No.: 86370

Place: Gurgaon

Date: May 17, 2017

**Saket City Hospitals Private Limited**  
**Balance sheet as at March 31, 2017**

	Notes	As at March 31, 2017	As at March 31, 2016	(Rs in Lacs) As at April 1, 2015
<b>ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and equipment	3	4,489	4,892	5,515
Capital work-in-progress	3	547	-	-
Intangible assets	4	28	41	54
Financial assets	5	-	-	6,612
(i) Loans		-	-	7,993
(ii) Trade receivables		-	-	-
(iii) Other financial assets		14,286	14,286	-
Other non current assets	6	7,341	7,036	-
		<b>26,691</b>	<b>26,255</b>	<b>20,174</b>
<b>Current assets</b>				
Inventories	7	-	3	7
Financial assets	8	-	-	348
(i) Loans		1,318	-	4,075
(ii) Trade receivables		195	1,277	39
(iii) Other financial assets		-	14	31
(iv) Cash and cash equivalents		15	27	3
(v) Other bank balances		-	3	521
Other current assets	9	285	663	5,024
		<b>1,813</b>	<b>1,987</b>	<b>5,024</b>
<b>TOTAL ASSETS</b>		<b>28,504</b>	<b>28,242</b>	<b>25,198</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Equity share capital	10	2,965	2,915	2,915
Other equity	10	(4,570)	(4,613)	(2,363)
<b>Total Equity</b>		<b>(1,605)</b>	<b>(1,698)</b>	<b>552</b>
<b>Non-current liabilities</b>				
<b>Financial Liabilities</b>				
(i) Borrowings	11	28,860	26,812	20,216
Long term provisions	12	14	23	20
		<b>28,874</b>	<b>26,835</b>	<b>20,236</b>
<b>Current liabilities</b>				
<b>Financial Liabilities</b>				
(i) Borrowings	13	310	1,349	-
(ii) Trade payables		356	1,064	755
(iii) Other financial liabilities		515	598	3,528
Short term provisions	14	15	27	24
Other current liabilities	15	39	67	103
		<b>1,235</b>	<b>3,105</b>	<b>4,410</b>
<b>TOTAL LIABILITIES</b>		<b>30,109</b>	<b>29,940</b>	<b>24,646</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>28,504</b>	<b>28,242</b>	<b>25,198</b>

Summary of significant accounting policies

2

Contingent liabilities, commitments and litigations

23

Other notes on accounts

24

The accompanying notes are integral part of the financial statements

**As per our report of even date attached**

**For S.R. Batliboi & Co. LLP**

Chartered Accountants

ICAI Firm Registration Number: 301003E/E300005

**For and on behalf of the Board of Directors of**

**Saket City Hospitals Private Limited**

Sd/-

per Atul Seksaria

Partner

Membership Number: 086370

Sd/-

Yogesh Kumar Sareen

(Director)

DIN:00884252

Sd/-

Kamalpati Kashyap

(Director)

DIN:02359002

Sd/-

Soubir Ghosh

(Head of Finance)

Sd/-

Poonam Makkar

(Company Secretary)

Membership No. FCS-7919

Place : Gurgaon

Date : May 17, 2017

Place : Gurgaon

Date : May 17, 2017



**Saket City Hospitals Private Limited**  
**Statement of profit and loss for the year ended March 31, 2017**

		(Rs in Lacs)	
	Notes	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>INCOME</b>			
Revenue from operations	16	2,225	4,952
Other income	17	43	3
Finance income	18	1,728	622
<b>Total income</b>		<b>3,996</b>	<b>5,577</b>
<b>EXPENSES</b>			
Purchase of pharmacy, drugs, consumables and implants		-	73
(Increase)/decrease in inventory of pharmacy, drugs and consumables and implants		3	4
Employee benefits expense	19	387	630
Finance costs	20	3,661	3,075
Depreciation and amortization expense	21	526	558
Other expenses	22	342	3,490
<b>Total expenses</b>		<b>4,919</b>	<b>7,830</b>
<b>Loss before tax</b>		<b>(923)</b>	<b>(2,253)</b>
Tax expense		-	-
<b>Loss after tax</b>		<b>(923)</b>	<b>(2,253)</b>
<b>Other comprehensive income</b>			
Other comprehensive income not to be reclassified to profit or loss in subsequent periods:			
Re-measurement gains/ (losses) on defined benefit plans		16	3
Income tax effect		-	-
		16	3
<b>Other comprehensive income for the year, net of tax</b>		<b>16</b>	<b>3</b>
<b>Total comprehensive income for the year, net of tax attributable to equity shareholder</b>		<b>(907)</b>	<b>(2,250)</b>
<b>Earnings per equity share (Nominal Value of share Rs. 10/-) (refer note 24.3)</b>			
Basic		(3.17)	(7.73)
Diluted		(3.11)	(7.73)
Summary of significant accounting policies	2		
Contingent liabilities, commitments and litigations	23		
Other notes on accounts	24		

The accompanying notes are integral part of the financial statements

**As per our report of even date attached**

**For S.R. Batliboi & Co. LLP**  
**Chartered Accountants**  
ICAI Firm Registration Number: 301003E/E300005

**Sd/-**  
**per Atul Seksaria**  
Partner  
Membership Number: 086370

**For and on behalf of the Board of Directors of**  
**Saket City Hospitals Private Limited**

**Sd/-**  
**Yogesh Kumar Sareen**  
(Director)  
DIN:00884252

**Sd/-**  
**Kamalpati Kashyap**  
(Director)  
DIN:02359002

**Sd/-**  
**Soubir Ghosh**  
(Head of Finance)

**Sd/-**  
**Poonam Makkar**  
(Company Secretary)  
Membership No. FCS-7919

Place : Gurgaon  
Date : May 17, 2017

Place : Gurgaon  
Date : May 17, 2017

**Saket City Hospitals Private Limited**  
**Statement of changes in equity for the year ended March 31, 2017**

**a) Equity share capital**

Particulars	Nos.	(Rs in Lacs)
As at April 1, 2015	29,146,700	2,915
Add: Equity share issued (refer note 10)	-	-
<b>As at March 31, 2016</b>	<b>29,146,700</b>	<b>2,915</b>
Add: Equity share issued (refer note 10)	-	-
<b>As at March 31, 2017</b>	<b>29,146,700</b>	<b>2,915</b>

**b) Compulsory convertible preference shares**

Particulars	No.	(Rs in Lacs)
As at April 1, 2015	-	-
Add: Compulsory convertible preference shares issued (refer note 10)	-	-
<b>As at March 31, 2016</b>	<b>-</b>	<b>-</b>
Add: Compulsory convertible preference shares issued (refer note 10)	500,000	50
<b>As at March 31, 2017</b>	<b>500,000</b>	<b>50</b>

**c) Other Equity**

Particulars	Reserve and surplus		Total equity
	Security premium account	Retained earnings	
As at April 1, 2015	-	(2,363)	(2,363)
Loss for the year	-	(2,253)	(2,253)
Other comprehensive income for the year	-	3	3
Addition on equity shares issued (refer note 10)	-	-	-
<b>As at March 31, 2016</b>	<b>-</b>	<b>(4,613)</b>	<b>(4,613)</b>
Loss for the year	-	(923)	(923)
Other comprehensive income for the year	-	16	16
Addition on Compulsory convertible preference shares issued (refer note 10)	950	-	950
<b>As at March 31, 2017</b>	<b>950</b>	<b>(5,520)</b>	<b>(4,570)</b>

Summary of significant accounting policies	2
Contingent liabilities, commitments and litigations	23
Other notes on accounts	24

The accompanying notes are integral part of the financial statements

**As per our report of even date attached**

**For S.R. Batliboi & Co. LLP**  
Chartered Accountants  
ICAI Firm Registration Number: 301003E/E300005

**For and on behalf of the Board of Directors of**  
**Saket City Hospitals Private Limited**

Sd/-  
**per Atul Seksaria**  
Partner  
Membership Number: 086370

Sd/-  
**Yogesh Kumar Sareen**  
(Director)  
DIN:00884252

Sd/-  
**Kamalpati Kashyap**  
(Director)  
DIN:02359002

Sd/-  
**Soubir Ghosh**  
(Head of Finance)

Sd/-  
**Poonam Makkar**  
(Company Secretary)  
Membership No. FCS-7919

Place : Gurgaon  
Date : May 17, 2017

Place : Gurgaon  
Date : May 17, 2017

**Saket City Hospitals Private Limited**  
**Statement of cash flows for the year ended March 31, 2017**

	(Rs in Lacs)	
	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>Cash flow from operating activities</b>		
Loss before tax	(923)	(2,253)
<b>Adjustments to reconcile profit before tax to net cash flows:</b>		
Depreciation of property, plant and equipment	513	545
Amortization of intangible assets	13	13
Profit on foreign exchange fluctuation	(2)	-
Unclaimed Balances & excess provisions written back	(39)	(3)
Loss on disposal of property, plant and equipment	-	80
Finance income (including fair value change in financial instruments)	(1,728)	(622)
Finance costs (including fair value change in financial instruments)	3,661	3,075
<b>Operating profit before working capital changes</b>	<b>1,495</b>	<b>835</b>
<b>Working capital adjustments:</b>		
Movements in provisions and gratuity	(5)	9
(Increase)/decrease in trade and other receivables and prepayments	1,361	(10,637)
Increase/(decrease) in trade and other payables	(695)	276
Decrease in inventories	3	4
<b>Cash generated from/(used in) operations</b>	<b>2,159</b>	<b>(9,513)</b>
Income tax paid	(192)	(11)
<b>Net cash flows from/(used in) operating activities</b>	<b>1,967</b>	<b>(9,524)</b>
	2	
<b>Cash flow from investing activities</b>		
Proceeds from sale of property, plant and equipment	-	19
Purchase of property, plant and equipment (including intangible assets, CWIP and capital advances)	(488)	(64)
Proceeds from fixed deposits under lien	3	-
Loan repaid by other healthcare service provider	-	6,960
Interest received	410	625
<b>Net cash flows from/(used in) investing activities</b>	<b>(75)</b>	<b>7,540</b>
<b>Cash flow from financing activities</b>		
Proceeds from issuance of Compulsory convertible preference shares capital including security premium, net of expenses incurred for shares issued	1,000	-
Interest paid	(3,461)	(3,196)
Proceeds from long term borrowings	1,596	3,827
Proceeds from short term borrowings (net of payment)	(1,039)	1,349
<b>Net cash flows from/(used in) financing activities</b>	<b>(1,904)</b>	<b>1,980</b>
Net (decrease) in cash and cash equivalents	(12)	(4)
Cash and cash equivalents at the beginning of the year	27	31
<b>Cash and cash equivalents at year end</b>	<b>15</b>	<b>27</b>

**Components of cash and cash equivalents :-**

	As at March 31, 2017	As at March 31, 2016
Balances with banks:		
On current accounts	15	27
	<b>15</b>	<b>27</b>

Summary of significant accounting policies	2
Contingent liabilities, commitments and litigations	23
Other notes on accounts	24

The accompanying notes are integral part of the financial statements

As per our report of even date attached

**For S.R. Batliboi & Co. LLP**  
Chartered Accountants  
ICAI Firm Registration Number: 301003E/E300005

**For and on behalf of the Board of Directors of**  
**Saket City Hospitals Private Limited**

**Sd/-**  
**per Atul Seksaria**  
Partner  
Membership Number: 086370

**Sd/-**  
**Yogesh Kumar Sareen**  
(Director)  
DIN:00884252

**Sd/-**  
**Kamalpati Kashyap**  
(Director)  
DIN:02359002

**Sd/-**  
**Soubir Ghosh**  
(Head of Finance)

**Sd/-**  
**Poonam Makkar**  
(Company Secretary)  
Membership No. FCS-7919

Place : Gurgaon  
Date : May 17, 2017

Place : Gurgaon  
Date : May 17, 2017

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**1 Corporate Information**

Saket City Hospitals Private Limited ("the Company") (Formerly known as G.M. Modi Hospitals Corporation Pvt. Ltd.) is a private company domiciled in India and incorporated under the provisions of the Companies Act, 2013. The Company is in the business of providing healthcare services, construction services, supply, erection and installation of equipments and other related services, and leasing of medical and other equipments on operating lease to Gujarmal Modi Hospital and Research Centre for Medical Sciences ("the Society").

**2 Significant accounting policies**

**2.1 Basis of preparation**

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Companies (Indian Accounting Standard) Rule, 2015. For all periods up to and including the year ended March 31, 2016, the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements for the year ended March 31, 2017 are the first financial statements which has been prepared in accordance with Ind AS notified under the Companies Indian Accounting Standards Rules, 2015. Refer note 27.15 for information on how the company has adopted Ind AS.

The standalone financial statements have been prepared on a historical cost basis, except for the following assets and liabilities which have been measured at fair value

- (i) Derivative financial instruments,
- (ii) Certain financial assets and financial liabilities
- (iii) Defined benefit plans - plan assets

Financial Statement are presented in INR and all values are rounded to nearest Lacs (INR 00,000) except when otherwise stated

**2.2 Summary of significant accounting policies**

**a. Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- (i) Expected to be realized or intended to be sold or consumed in normal operating cycle
- (ii) Held primarily for the purpose of trading
- (iii) Expected to be realized within twelve months after the reporting period, or
- (iv) Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- (i) It is expected to be settled in normal operating cycle
- (ii) It is held primarily for the purpose of trading
- (iii) It is due to be settled within twelve months after the reporting period, or
- (iv) There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

**b. Property, Plant and Equipment**

Under the previous GAAP (Indian GAAP), all assets were carried in the balance sheet at cost, less accumulated depreciation and accumulated impairment losses, if any. On the date of transition to IND AS, the Company has applied exemptions of Ind AS 101 to continue the carrying value of all property, plant and equipment as at the date of transition as its deemed cost.

Property, Plant and equipment including capital work in progress are stated at cost, less accumulated depreciation and accumulated impairment losses, if any. The cost comprises of purchase price, taxes, duties, freight and other incidental expenses directly attributable and related to acquisition and installation of the concerned assets and are further adjusted by the amount of CENVAT credit and VAT credit availed wherever applicable. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their respective useful lives. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in profit or loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognized.

The company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset.

Capital work- in- progress includes cost of property, plant and equipment under installation / under development as at the balance sheet date.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Depreciation on property, plant and equipment is provided on prorata basis on straight-line method using the useful lives of the assets estimated by management and in the manner prescribed in Schedule II of the Companies Act 2013. The useful life is as follows:

<b>Assets</b>	<b>Useful lives estimated by the management (years)</b>
Medical Equipment	13 Years
Electrical Installations and Equipments	10 Years
Plant and Equipment	15 Years
Office Equipment	5 Years
Computers & Data Processing Units	3 - 6 Years
Furniture and Fixtures	10 Years
Motor Vehicles	6 - 8 Years

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**c. Intangible assets**

**Separately acquired intangible assets**

The Company has applied exemptions of Ind AS 101 to continue the carrying value of intangible assets at the date of transition as its deemed cost in accordance with Ind AS 101 First Time adoption. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangibles, excluding capitalized development cost, are not capitalized and the related expenditure is reflected in statement of Profit and Loss in the period in which the expenditure is incurred. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use.

**Research and development cost**

Research costs are expensed as incurred. Development expenditure incurred on an individual project is recognized as an intangible asset when the Company can demonstrate all the following:

- i) The technical feasibility of completing the intangible asset so that it will be available for use or sale;
- ii) Its intention to complete the asset;
- iii) Its ability to use or sale the asset;
- iv) How the asset will generate future economic benefits;
- v) The availability of adequate resources to complete the development and to use or sale the asset; and
- vi) The ability to measure reliably the expenditure attributable to the intangible asset during development.

Following the initial recognition of the development expenditure as an asset, the cost model is applied requiring the asset to be carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized on straight line basis over the estimated useful life. During the period of development, the asset is tested for impairment annually.

The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life is reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in the statement of profit and loss in the expense category consistent with the function of the intangible assets.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from disposal of the intangible assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the assets are disposed off.

Intangible assets with finite useful life are amortized on a straight line basis over their estimated useful life of 2-7 years.

**d. Impairment of non financial assets**

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's, recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used.

The Company bases its impairment calculation on detailed budgets and forecast calculations which are prepared separately for each of the Company's cash-generating units to which the individual assets are allocated. These budgets and forecast calculations are generally covering a period of five years. For the remaining economic life of the asset or cash-generating unit (CGU), a long term growth rate is calculated and applied to project future cash flows after the fifth year.

Impairment losses including impairment on inventories, are recognized in the statement of profit and loss.

After impairment, depreciation is provide on the revised carrying amount of the asset over its remaining economic life.

An assessments is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the Company estimates the asset's or cash-generating unit's recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of profit and loss unless the asset is carried at a revalued amount, in which case the reversal is treated as a revaluation increase.

**e. Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**(i) Financial assets**

The Company classified its financial assets in the following measurement categories :-

- Those to be measured subsequently at fair value (either through other comprehensive income or through profit & loss)
- Those measured at amortized cost

**Initial recognition and measurement**

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

**Subsequent measurement**

For purposes of subsequent measurement, financial assets are classified in four categories:

- (i) Debt instruments at amortized cost
- (ii) Debt instruments at fair value through other comprehensive income (FVTOCI)
- (iii) Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- (iv) Equity instruments measured at fair value through other comprehensive income (FVTOCI)

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**Debt instruments at amortized cost**

A 'debt instrument' is measured at the amortized cost if both the following conditions are met:

- (i) Business model test : The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows (rather than to sell the instrument prior to its contractual maturity to released its fair value change), and
- (ii) Cash flow characteristics test : Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate (EIR) method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. EIR is the rate that exactly discount the estimated future cash receipts over the expected life of the financial instrument or a shorter period, where appropriate to the gross carrying amount of financial assets. When calculating the effective interest rate the company estimate the expected cash flow by considering all contractual terms of the financial instruments. The EIR amortization is included in finance income in the profit or loss. The losses arising from impairment are recognized in the profit or loss. This category generally applies to trade and other receivables.

**Debt instruments at fair value through OCI**

A debt instrument is measured at fair value through other comprehensive income if following criteria are met:

- a) Business Model Test : The objective of financial instrument is achieved by both collecting contractual cash flows and for selling financial assets.
- b) Cash flow characteristics test: The contractual terms of the debt instrument give rise on specific dates to cash flows that are solely payments of principal and interest on principal amount outstanding.

Debt instrument included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income (OCI), except for the recognition of interest income, impairment gains or losses and foreign exchange gains or losses which are recognized in statement of profit and loss. On derecognition of asset, cumulative gain or loss previously recognized in OCI is reclassified from the equity to statement of profit & loss. Interest earned whilst holding FVTOCI financial asset is reported as interest income using the EIR method.

**Debt instruments at FVTPL**

FVTPL is a residual category for financial instruments. Any financial instrument, which does not meet the criteria for amortized cost or FVTOCI, is classified as at FVTPL. A gain or loss on a Debt instrument that is subsequently measured at FVTPL and is not a part of a hedging relationship is recognized in statement of profit or loss and presented net in the statement of profit and loss within other gains or losses in the period in which it arises. Interest income from these Debt instruments is included in other income.

**Equity investments of other entities**

All equity investments in scope of IND AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which IND AS103 applies are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income all subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to profit and loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Profit and loss.

**Derecognition**

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognized (i.e., removed from the Company's statement of financial position) when:

- the rights to receive cash flows from the asset have expired, or
- the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass through" arrangement and either;

- (a) the Company has transferred the rights to receive cash flows from the financial assets or
- (b) the Company has retained the contractual right to receive the cash flows of the financial asset, but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the Company has transferred an asset, the Company evaluates whether it has transferred substantially all the risks and rewards of the ownership of the financial assets. In such cases, the financial asset is derecognized. Where the entity has not transferred substantially all the risks and rewards of the ownership of the financial assets, the financial asset is not derecognized.

Where the Company has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is derecognized if the Company has not retained control of the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognized to the extent of continuing involvement in the financial asset.

**Impairment of financial assets**

In accordance with IND AS 109, the Company applies expected credit losses (ECL) model for measurement and recognition of impairment loss on the following financial asset and credit risk exposure

- Financial assets measured at amortized cost;
- Financial assets measured at fair value through other comprehensive income (FVTOCI);

The Company follows "simplified approach" for recognition of impairment loss allowance on trade receivables. Under the simplified approach, the Company does not track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. the Company uses a provision matrix to determine impairment loss allowance on the portfolio of trade receivables. The provision matrix is based on its historically observed default rates over the expected life of trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward looking estimates are analyzed.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the Company reverts to recognizing impairment loss allowance based on 12- months ECL.

**Reclassification of financial assets**

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognized gains, losses (including impairment gains or losses) or interest.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**(ii) Financial liabilities**

**Initial recognition and measurement**

Financial liabilities are classified at initial recognition as financial liabilities at fair value through profit or loss, loans and borrowings, and payables, net of directly attributable transaction costs. The Company financial liabilities include loans and borrowings including bank overdraft, trade payable, trade deposits, retention money and other payables.

The measurement of financial liabilities depends on their classification, as described below:

**Trade Payables**

These amounts represents liabilities for goods and services provided to the Company prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at fair value and subsequently measured at amortized cost using EIR method.

**Financial liabilities at fair value through profit or loss**

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. Gains or losses on liabilities held for trading are recognized in the statement of profit and loss. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in IND AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ loss are not subsequently transferred to profit and loss. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the statement of profit or loss. The Company has not designated any financial liability as at fair value through profit and loss.

**Loans and borrowings**

Borrowings are initially recognized at fair value, net of transaction cost incurred. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognised as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit and loss.

**Financial guarantee contracts**

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognized initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of IND AS 109 and the amount recognized less cumulative amortization.

**Derecognition**

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit and loss.

**Offsetting of financial instruments**

Financial assets and financial liabilities are offset and the net amount is reported in the standalone balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

**f. Revenue recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

However, sales tax/value added tax (VAT) is not received by the Company on its own account. Rather, it is tax collected on value added to the commodity by the seller on behalf of the government. Accordingly, it is excluded from revenue.

The specific recognition criteria described below must also be met before revenue is recognized.

**Sale of goods**

Revenue from sale of pharmacy and pharmaceutical supplies is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer usually on delivery of goods. The Company collects sales tax and value added taxes (VAT) on behalf of the government and, therefore, these are not economic benefits flowing to the Company. Hence, they are excluded from revenue. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Revenue is usually recognized when it is probable that economic benefits associated with the transaction will flow to the entity, amount of revenue can be measured reliably and entity retained neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold.

**Rendering of services**

Revenue from healthcare services (including drugs, consumables and implants used in delivery of such services) are recognized on the performance of related services and includes service for patients undergoing treatment and pending for billing, which is shown as unbilled under other current assets. Revenues from other healthcare service providers and sponsorship and educational income are recognized on the performance of related services as per the terms of contracts.

**Rental income**

Rental income arising from operating leases on investment properties is accounted for on a straight-line basis over the lease terms and is included in revenue in the statement of profit or loss due to its operating nature.

**Interest**

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.

**g. Inventories**

Inventories comprise of pharmacy, drugs, consumable and implants which are valued at lower of cost and net realizable value. Cost includes the cost of purchase, duties, taxes (other than those recoverable from tax authorities) and other cost incurred in bringing the inventories to their present location and condition. Cost is determined on first in first out basis.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**h. Taxes**

**Current income tax**

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income Tax Act, 1961 and the income computation and disclosure standards (ICDS) enacted in India by using tax rates and tax laws that are enacted or substantively enacted, at the reporting date.

Current income tax relating to items recognized outside profit or loss is recognized outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate, if any.

**Deferred tax**

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized, except:

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside the statement of profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

**i. Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

**j. Leases**

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

For arrangements entered into prior to 1 April 2015, the Company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

**Company as a lessee**

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease.

Finance leases are capitalized at the commencement of the lease at the inception date at fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognized in finance costs in the statement of profit and loss, unless they are directly attributable to qualifying assets, in which case they are capitalized in accordance with the Company's general policy on the borrowing costs (see note 2.2 i).

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term.

Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term unless the payment are structured to increase in line with expected general inflation to compensate for the losses in expected inflationary cost increase.

**Company as a lessor**

Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognized on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized over the lease term on the same basis as rental income. Contingent rent are recognized as revenue in the period in which they are earned.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Company to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

**k. Provisions**

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

**Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases, where there is a liability that cannot be recognized because it cannot be measured reliably. the Company does not recognize a contingent liability but discloses its existence in the financial statements unless the probability of outflow of resources is remote.

Provisions, contingent liabilities, contingent assets and commitments are reviewed at each balance sheet date.



**l. Employee benefits**

**Provident Fund and Family Pension Fund**

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as an expenditure, when an employee renders the related service. If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognized as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognized as an asset to the extent that the pre payment will lead to, for example, a reduction in future payment or a cash refund.

**Gratuity**

The Company operates a defined benefit plans for its employees for gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out using the projected unit credit method. Actuarial gains and losses are recognized in full in the period in which they occur in the statement of profit and loss.

**Compensated Absences**

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. However, the Company presents the leave as a current liability in the balance sheet as it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

**Short-term obligations**

Liabilities for wages and salaries, including non monetary benefits that are expected to be settled wholly within twelve months after the end of the period in which the employees render the related service are recognized in respect of employee service up to the end of the reporting period and are measured at the amount expected to be paid when the liabilities are settled. the liabilities are presented as current employee benefit obligations in the balance sheet.

**m. Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

**n. Earning per share**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

**o. Foreign currencies**

Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). the Company's financial statements are presented in Indian rupee ('Rs.') which is also the Company's functional and presentation currency.

Foreign currency transactions are recorded on initial recognition in the functional currency, using the exchange rate prevailing at the date of transaction.

Measurement of foreign currency items at the balance sheet date

Foreign currency monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

Exchange differences arising on settlement or translation of monetary items are recognized as income or expense in the period in which they arise with the exception of exchange differences on gain or loss arising on translation of non-monetary items measured at fair value which is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognized in OCI or profit or loss are also recognized in OCI or profit or loss, respectively).

**p. Fair value measurement**

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- (i) In the principal market for the asset or liability, or
- (ii) In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- (i) Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- (ii) Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- (iii) Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

### **2.3 Standards issued but not yet effective**

The amendments to standards that are issued, but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company intends to adopt these standards, if applicable, when they become effective.

The Ministry of Corporate Affairs (MCA) has issued the Companies (Indian Accounting Standards) Amendment Rules, 2017 and has amended the following standard:

#### **Amendments to Ind AS 7, Statement of Cash Flow**

The amendments to Ind AS 7 requires an entity to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes. On initial application of the amendment, entities are not required to provide comparative information for preceding periods. These amendments are effective for annual periods beginning on or after 1 April 2017. Application of this amendments will not have any recognition and measurement impact. However, it will require additional disclosure in the financial statements.

#### **Amendments to Ind AS 102, Share-based payment**

The MCA has issued amendments to Ind AS 102 that address three main areas: the effects of vesting conditions on the measurement of a cash-settled share-based payment transaction, the classification of a share-based payment transaction with net settlement features for withholding tax obligations, and accounting where a modification to the terms and conditions of a share-based payment transaction changes its classification from cash settled to equity settled. The amendments are effective for annual periods beginning on or after 1 April 2017. The Company is assessing the potential effect of the amendments on its financial statements.

The Company will adopt these amendments, if applicable from their applicability date.

### **2.4 Significant accounting judgements, estimates and assumptions**

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

#### **Judgements**

In the process of applying the Company's accounting policies, management has made the following judgements, which have the most significant effect on the amounts recognized in the financial statements.

##### **(a) Operating lease commitments - Company as lessee**

The Company has taken various commercial properties on leases. The Company has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a substantial portion of the economic life of the commercial property, and that it does not retain all the significant risks and rewards of ownership of these properties and accounts for the contracts as operating leases.

#### **Estimates and assumptions**

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

##### **(a) Taxes**

Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range of business relationships and the long term nature and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. The Company establishes provisions, based on reasonable estimates. The amount of such provisions is based on various factors, such as experience of previous tax audits and differing interpretations of tax regulations by the taxable entity and the responsible tax authority. Such differences of interpretation may arise on a wide variety of issues depending on the conditions prevailing in the respective domicile of the companies.

##### **(b) Gratuity benefit**

The cost of defined benefit plans (i.e. Gratuity benefit) is determined using actuarial valuations. An actuarial valuation involves making various assumptions which may differ from actual developments in the future. These include the determination of the discount rate, future salary increases, mortality rates and future pension increases. Due to the complexity of the valuation, the underlying assumptions and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date. In determining the appropriate discount rate, management considers the interest rates of long term government bonds with extrapolated maturity corresponding to the expected duration of the defined benefit obligation. The mortality rate is based on publicly available mortality tables for the specific countries. Future salary increases and pension increases are based on expected future inflation rates. Further details about the assumptions used, including a sensitivity analysis, are given in Note 24.1.

##### **(c) Fair value measurement of financial instrument**

When the fair value of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the Discounted Cash Flow (DCF) model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

##### **(d) Impairment of Financial assets**

The impairment provisions of financial assets are based on assumptions about risk of default and expected loss rates. The Company uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on Company's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

##### **(e) Impairment of non-Financial assets**

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's CGU's fair value less cost of disposal and its value in use. It is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, or other fair value indicators.

Saket City Hospitals Private Limited  
Notes forming part of the financial statements

3. Property, plant and equipments (PPE)

(Rs in Lacs)

	Freehold land	Medical equipment	Office equipment	Furniture and fixture	Motor vehicles	Computers and data processing units	Electrical installations and equipment	Total	Capital work in progress
<b>At cost</b>									
<b>Deemed cost as at April 1, 2015</b>	-	5,310	78	15	52	52	8	5,515	-
Additions	-	-	-	-	21	-	-	21	-
Disposals	-	174	6	-	24	3	-	207	-
<b>As at March 31, 2016</b>	-	5,136	72	15	49	49	8	5,329	-
Additions	6	104	-	-	-	-	-	110	547
Disposals	-	-	-	-	-	-	-	-	-
<b>As at March 31, 2017</b>	6	5,240	72	15	49	49	8	5,439	547
<b>Depreciation</b>									
<b>As at April 1, 2015</b>	-	-	-	-	-	-	-	-	-
Additions	-	468	24	2	11	39	1	545	-
Disposals	-	100	1	-	5	2	-	108	-
<b>As at March 31, 2016</b>	-	368	23	2	6	37	1	437	-
Additions	-	466	23	2	9	11	2	513	-
Disposals	-	-	-	-	-	-	-	-	-
<b>As at March 31, 2017</b>	-	834	46	4	15	48	3	950	-
<b>Net carrying amount</b>									
<b>As at March 31, 2017</b>	6	4,406	26	11	34	1	5	4,489	547
<b>As at March 31, 2016</b>	-	4,768	49	13	43	12	7	4,892	-
<b>As at April 1, 2015</b>	-	5,310	78	15	52	52	8	5,515	-

3.01 Land is freehold and mortgaged to bank.

3.02 Medical equipment & Other fixed assets are given on operating lease to Gujarmal Modi Hospital & Research centre for Medical Sciences.

	(Rs in Lacs)		
	March 31, 2017	March 31, 2016	April 1, 2015
Gross block	3,759	3,196	3,250
Depreciation charge for the year	357	333	-
Accumulated depreciation	690	333	-
<b>Net book value</b>	<b>3,069</b>	<b>2,863</b>	<b>3,250</b>

3.03 PPE given as security

PPE are subject to charge to secure the Company's secured long term borrowings as disclosed in note 11.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**4. Intangible assets**

	<b>(Rs in Lacs)</b>
	<b>Computer software</b>
<b>At cost</b>	
<b>Deemed cost as at April 1, 2015</b>	<b>54</b>
Additions	-
Disposals	1
<b>As at March 31, 2016</b>	<b>53</b>
Additions	-
Disposals	-
<b>As at March 31, 2017</b>	<b>53</b>
<b>Amortization</b>	
<b>As at April 1, 2015</b>	<b>-</b>
Additions	13
Disposals	1
<b>As at March 31, 2016</b>	<b>12</b>
Additions	13
Disposals	-
<b>As at March 31, 2017</b>	<b>25</b>
<b>Net carrying amount</b>	
<b>As at March 31, 2017</b>	<b>28</b>
<b>As at March 31, 2016</b>	<b>41</b>
<b>As at April 1, 2015</b>	<b>54</b>

**4.01** Computer software are given on operating lease to Gujarmal Modi Hospital & Research centre for Medical Sciences.

	<b>(Rs in Lacs)</b>		
	March 31, 2017	March 31, 2016	April 1, 2015
Gross block	53	53	53
Depreciation charge for the year	13	13	-
Accumulated	26	13	-
<b>Net book value</b>	<b>27</b>	<b>40</b>	<b>53</b>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

(Rs in Lacs)

	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
<b>5. Non-current financial assets</b>			
<b>(i) Loans (Valued at amortized cost) (Unsecured considered good)</b>			
Loans and advances to other healthcare service providers	-	-	6,612
	<u>-</u>	<u>-</u>	<u>6,612</u>
<b>(ii) Trade receivables</b>			
Trade receivables - considered good	-	-	7,993
	<u>-</u>	<u>-</u>	<u>7,993</u>
<b>(iii) Other financial assets (Value at amortized cost)</b>			
Security deposits	14,286	14,286	-
	<u>14,286</u>	<u>14,286</u>	<u>-</u>
<b>6. Other non current assets (Unsecured considered good)</b>			
Prepaid expenses	6,957	7,036	-
Tax deducted at source recoverable	384	-	-
	<u>7,341</u>	<u>7,036</u>	<u>-</u>
<b>7. Inventories</b>			
Stock of pharmacy, drugs, consumables and implants (at lower of cost and net realisable value)	-	3	7
	<u>-</u>	<u>3</u>	<u>7</u>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

	(Rs in Lacs)		
	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
<b>8. Current financial assets</b>			
<b>(i) Loans</b>			
Loans and advances to other healthcare service providers	1,318	-	348
	<u>1,318</u>	<u>-</u>	<u>348</u>
<b>(ii) Trade receivables</b>			
<b>Unsecured :-</b>			
Trade receivables - considered good	195	1,277	4,075
	<u>195</u>	<u>1,277</u>	<u>4,075</u>
<b>(iii) Other financial assets</b>			
Unbilled revenue	-	14	35
Interest accrued on income tax refund	-	-	4
	<u>-</u>	<u>14</u>	<u>39</u>
<b>(iv) Cash and cash equivalents</b>			
<b>Balances with banks:</b>			
On current accounts	15	27	30
Cash on hand	-	-	1
	<u>15</u>	<u>27</u>	<u>31</u>
<b>(v) Other bank balances</b>			
<b>Deposit :</b>			
Fixed deposits under lien #	-	3	3
	<u>-</u>	<u>3</u>	<u>3</u>
<p># Fixed deposits Nil (March 31, 2016 : Rs.3 Lacs) (April 1, 2015 : Rs.3 Lacs) are in the nature of margin money kept with bank guarantee issued by the bank and are deposited against sales tax registration.</p>			
<b>9. Other current assets (Unsecured considered good, unless otherwise stated)</b>			
Tax deducted at source recoverable	151	343	332
MAT credit entitlement	2	2	2
Balance with statutory authorities	-	164	176
<b>Other advances :-</b>			
Unsecured, considered good	4	3	5
Unsecured, considered doubtful	11	11	11
Less: Provision for doubtful advances	(11)	(11)	(11)
Prepaid expenses	128	151	6
	<u>285</u>	<u>663</u>	<u>521</u>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
Notes forming part of the financial statements

**10. Share capital and other equity**

**(i) Equity**

	(Rs in Lacs)		
	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
<b>Authorised</b>			
5,00,00,000 (Previous Year 7,00,00,000) Equity Shares of Rs. 10/- each	5,000	7,000	7,000
2,00,00,000 (Previous year Nil) Preference Shares of Rs. 10/- each	2,000	-	-
	<b>7,000</b>	<b>7,000</b>	<b>7,000</b>

**Issued, subscribed and fully paid-up**

2,91,46,700 (March 31, 2016: 2,91,46,700) (April 1, 2015: 2,91,46,700) equity shares of Rs.10/- each	2,915	2,915	2,915
5,00,000 (March 31, 2016 : Nil) (April 1, 2015 : Nil) compulsory convertible preference shares of Rs.10/- each	50	-	-
<b>Total issued, subscribed and fully paid-up share capital</b>	<b>2,965</b>	<b>2,915</b>	<b>2,915</b>

**Reconciliation of the shares outstanding at the beginning and at the end of the reporting period**

Equity shares	March 31, 2017		March 31, 2016	
	No. of shares	(Rs in Lacs)	No. of shares	(Rs in Lacs)
At the beginning of the year	29,146,700	2,915	29,146,700	2,915
Issued during the year	-	-	-	-
- Fresh Issue	-	-	-	-
	<b>29,146,700</b>	<b>2,915</b>	<b>29,146,700</b>	<b>2,915</b>

**Reconciliation of compulsory convertible preference shares outstanding at the beginning and at the end of the reporting period**

Equity shares	March 31, 2017		March 31, 2016	
	No. of shares	(Rs in Lacs)	No. of shares	(Rs in Lacs)
At the beginning of the year	-	-	-	-
Issued during the year	500,000	50	-	-
- Fresh Issue	-	-	-	-
	<b>500,000</b>	<b>50</b>	<b>-</b>	<b>-</b>

**Details of shareholders holding more than 5% shares in the Company**

Name of the Shareholder	March 31, 2017		March 31, 2016		April 1, 2015	
	No. of shares	% held	No. of shares	% held	No. of shares	% held
<b>Equity Shares of Rs. 10 each fully paid</b>						
Max Healthcare Institute Limited, the holding company*	14,864,817	51%	14,864,817	51%	-	-
Smart Health City Pte Ltd., Singapore**	14,281,883	49%	14,281,883	49%	29,146,700	100%

\*Out of above, equity shares held by Smart Health City Pte Limited, 10 shares are held by Mr. G S Negi as nominee of Smart Health City Pte Limited.

\* Out of the equity shares held by Smart Health City Pte Limited as on 31st March 2015, Max Healthcare Institute Limited has acquired 14,864,817 equity shares on 27th November 2015, representing 51% holding.

**Details of compulsory convertible preference shareholders more than 5% shares in the Company**

Name of the Shareholder	March 31, 2017		March 31, 2016		April 1, 2015	
	No. of shares	% held	No. of shares	% held	No. of shares	% held
<b>Compulsory convertible preference shares of Rs. 10 each fully paid</b>						
Max Healthcare Institute Limited, the holding company	500,000	100%	-	-	-	-

**Terms/ rights attached to equity shares :-**

(i) Each holder of equity shares is entitled to one vote per share.

(ii) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) Max Healthcare Institute Limited has a call option right to require Smart Health City Pte Limited to sell all its holding in the equity shares of the Company at an aggregate amount of Rs. 37,500 Lacs with 12% return per annum compounded annually calculated for the period between the completion date and the date of such payment to Smart Health City Pte Limited in accordance with the share holding agreement dated November 27, 2015.

(iv) Smart Health City Pte Limited has the right to nominate two Directors to the Board who would be non-executive directors. Max Healthcare Institute Limited has the right to nominate all the other Directors who shall be in Majority.

(v) Director nominated by Smart Health City Pte Limited shall be the Non-executive Chairman of the Board for the initial period. after the initial period or in the event the Chairman resigns or is unable to act as a director of a Company under the Act, One of the directors nominated by Max Healthcare Institute Limited shall be appointed as the Chairman.

(vi) One of the directors nominated by Max Healthcare Institute Limited shall be appointed as the Vice Chairman of the board.

(vii) Out of above equity shares held by Max Healthcare Institute Limited, 25.5% of the equity shares are pledged with Yes Bank Limited and another 25.5% of the equity shares are pledged with Axis Bank Limited as a security for term loan granted to the Company. Further, Axis Bank Limited has negative lien for 21% equity shares of the Company.

**Terms/ rights attached to compulsory convertible preference shares (CCPS):-**

(i) The conversion period is earlier of the date on which Smart Health City Pte Limited cease to hold equity share of the company, in terms of shareholders' agreement dated 27th November, 2015 executed amongst the company, Max Healthcare Institute Limited and Smart Health City Pte Limited or 15(Fifteen) years from date of such subscription.

(ii) Each CCPS will be Compulsory converted into equity share of Rs. 10/- each at the higher of Fair market value as on the date of conversion subject to cap of Rs. 350/- per equity share or Rs. 10/- per equity share.

(iii) Coupon rate is 0%.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**(ii) Other equity**

	(Rs in Lacs)		
	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
Securities premium account (refer note a below)	950	-	-
Retained earnings (refer note b below)	(5,520)	(4,613)	(2,363)
	<u>(4,570)</u>	<u>(4,613)</u>	<u>(2,363)</u>
<b>a) Securities premium account</b>			
Balance at the beginning of the year	-	-	
Add: premium on issue of compulsory convertible preference shares	950	-	
Balance at the end of the year	<u>950</u>	<u>-</u>	
<b>b) Retained earnings</b>			
Balance at the beginning of the year	(4,613)	(2,363)	
Loss for the year	(923)	(2,253)	
Items of other comprehensive income recognised directly in retained earnings			
Re-measurement of post employment benefit obligation (net of tax) (item of OCI)	16	3	
Balance at the end of the year	<u>(5,520)</u>	<u>(4,613)</u>	

[This space has been intentionally left blank]



**Saket City Hospitals Private Limited**  
Notes forming part of the financial statements

**11. Borrowings**

	(Rs in Lacs)		
	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
<b>Non-current borrowings:-</b>			
<b>Term loans (secured)</b>			
From bank	26,760	24,949	-
<b>Finance lease obligation (secured)</b>			
Long term maturities of finance lease obligation	-	1,651	2,094
<b>Vehicle loans (secured)</b>	-	12	7
<b>Inter corporate deposits (unsecured)</b>	2,100	200	15,305
<b>Inter corporate deposits (secured)</b>	-	-	2,810
<b>Current borrowings :-</b>			
<b>Term loans (secured)</b>			
From bank	124	122	-
<b>Finance lease obligation (secured)</b>			
Current maturities of finance lease obligation	-	459	402
<b>Vehicle loans (secured)</b>	-	9	3
<b>Inter corporate deposits (unsecured)</b>	218	4	2,863
<b>Inter corporate deposits (secured)</b>	-	-	216
	<u>29,202</u>	<u>27,406</u>	<u>23,700</u>
<b>Less: Amount clubbed under "other current financial liabilities" [refer note 13 (iii)]</b>	<u>342</u>	<u>594</u>	<u>3,484</u>
	<u><u>28,860</u></u>	<u><u>26,812</u></u>	<u><u>20,216</u></u>
<b>Aggregate secured loans</b>	<b>26,884</b>	<b>27,202</b>	<b>5,532</b>
<b>Aggregate unsecured loans</b>	<b>2,318</b>	<b>204</b>	<b>18,168</b>

**Term loan from bank include :-**

(i) Rs.12,473 Lacs (March 31, 2016: Rs.12,463 Lacs) (April 01, 2015 : Nil) from Axis Bank Limited repayable in 52 quarterly installment from January, 2019. The loan is secured by way of:

- A first pari passu charge on all borrowers movables and immovable (if any acquired in future), including but not limited to movable plant and machinery, machinery, spares, tools and accessories, furniture, fixture, and all other movable assets, intangible, goodwill, uncalled capital, both present and future.
- A first pari passu charge by way of assignment/hypothecation/creation of security interest, including but not limited to, of all the rights, title, interest, benefits, claims and demands whatsoever of the Borrower in all documents executed by the borrower with SHRC including but not limited to the Hospital Service Agreement, both present and future.
- First pari passu charge on all receivables, current assets, present and future, of the borrower.
- Pledge of 25.50% share capital (on a fully diluted basis) of the borrower (in Compliance with BR Act) and option to increase it to 51% subject to inclusion of new lenders; and
- Negative lien for the remaining 21% shareholding of the borrower total aggregate percentage of pledge and negative lien not to exceed 51% of share capital at any time.
- Corporate guarantee by Max Healthcare Institute Limited.

(ii) Rs.14,410 Lacs (March 31, 2016: Rs.12,608 Lacs) (April 01, 2015 : Nil) from Yes Bank Limited repayable in 48 quarterly instalment from November, 2018. The loan is secured by way of:

- First pari passu charge over all movable fixed assets (both present and future) and immovable (if any acquired in future) of the borrower.
- First pari passu charge over all current assets (both present and future) of the borrower.
- First pari passu charge on book debts, operating cash flows, receivables, commissions, revenues, intangibles, goodwill (of whatsoever nature and wherever arising) of the borrower.
- Unconditional and irrevocable corporate guarantee of Max Healthcare Institute Limited to remain valid during entire tenor of facilities.
- assignment of all borrowers rights under the service agreement and any other such agreement for providing any other services to Saket City Hospitals Private Limited, letter of credit, guarantee, or performance bond provided by any party for any contract related to the Hospital project in favor of the borrower.
- Assignment of all the contracts, documents, insurance policies, rights, titles, permits/approvals, clearances and interest of the borrower pertaining to the Hospital project on first pari passu basis.
- Pledge of 25.5% equity shares of the borrower held by Max Healthcare Institute Limited.

**Finance lease obligation include :-**

Nil (March 31, 2016: 2,110 Lacs) (April 1, 2015: Rs.2,496 Lacs) The amount is secured by first charge on medical equipments purchased under this arrangement. The loan is further secured by way of corporate guarantee issued in favour of Philips India Limited by Smart Value Ventures Private Limited.

**Vehicle loan :-**

Vehicle loans of Nil (March 31, 2016: Rs.21 Lacs) (April 1, 2015: Rs.10 Lacs) are secured by way of hypothecation of respective vehicles.

**Inter corporate deposit (secured) :-**

Inter corporate deposits loan of Nil (March 31, 2016: Nil) (April 1, 2015 : Rs.3,026 Lacs) The loan is secured by mortgaging the equipments.

**Inter corporate deposit (unsecured) :-**

- Inter corporate deposits of Nil (March 31, 2016: Nil) (April 01, 2015: Rs.1,165 Lacs) from Avon Mercantile Limited repayable on the expiry of the term of the loan.
- Inter corporate deposits of Nil (March 31, 2016: Nil) (April 01, 2015: Rs.17,003 Lacs) from Smart Value Ventures Private Limited Avon Mercantile Limited repayable on the expiry of the term of the loan.
- Loan of Rs.2,318 Lacs (March 31, 2016: Rs. 204 Lacs) (April 01, 2015: Nil) from Max Healthcare Institute Limited repayable after fifteen years from the date of first installment.

Saket City Hospitals Private Limited  
Notes forming part of the financial statements

	(Rs in Lacs)		
	As at March 31, 2017	As at March 31, 2016	As at April 1, 2015
<b>12. Long term provision</b>			
<b>Provision for employee benefits</b>			
Provision for gratuity (refer note 24.1)	14	23	20
	<u>14</u>	<u>23</u>	<u>20</u>
<b>13. Current financial liabilities</b>			
<b>(i) Borrowings</b>			
Cash credit from banks	310	1,349	-
	<u>310</u>	<u>1,349</u>	<u>-</u>
<p>Cash credit loan of Rs.310 Lacs (March 31, 2016: Rs.604 Lacs) (April 1, 2015 : Nil) from Yes Bank Limited bearing interest @ yes bank base rate plus 1.15% i.e presently @ 10.25% per annum payable monthly and is secured by way of :</p> <p>a) A first pari passu charge over Company's all present and future, moveable and immoveable, tangible and intangible fixed assets excluding fixed assets pledged to other lenders and current assets.</p> <p>b) Pledge of 25.5% equity shares of the company held by Max Healthcare Institute Limited, the holding company.</p> <p>c) Unconditional and irrevocable corporate guarantee of the holding Company, Max Healthcare Institute Limited, to remain valid during entire tenor of facilities.</p> <p>Cash credit loan of Rs. Nil (March 31, 2016: Rs.745 Lacs) (April 1, 2015 : Nil) from Axis Bank Limited base rate plus 1.95% i.e presently @ 11.20% payable monthly and is secured by way of :</p> <p>a) A first pari passu charge over Company's all present and future, moveable and immoveable, tangible and intangible fixed assets excluding fixed assets pledged to other lenders and current assets.</p> <p>b) Pledge of 25.5% equity shares of the company held by Max Healthcare Institute Limited, the holding company.</p> <p>c) Unconditional and irrevocable corporate guarantee of the holding Company, Max Healthcare Institute Limited, to remain valid during entire tenor of facilities.</p> <p>d) Further, there is negative lien for 21% shareholding of the Company.</p>			
<b>(ii) Trade payables</b>			
Total outstanding dues of micro enterprises and small enterprises*	-	-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises #	356	1,064	755
	<u>356</u>	<u>1,064</u>	<u>755</u>
<p>* Details of dues to micro and small enterprises as per MSMED Act, 2006</p> <p>As per the Act, the Company is required to identify the Micro and small suppliers and pay them interest on overdue beyond the specified period irrespective of the terms agreed with such suppliers. Based on the information available with the Company, none of the creditors have confirmed the applicability of act on them. Hence, the liability of the interest and disclosure are not required to be disclosed in the financial statements.</p> <p># Trade payable includes due to related parties Rs.200 Lacs ( March 31, 2016 : Rs.46 Lacs) (April 1, 2015 : Nil)</p>			
<b>(iii) Other current financial liabilities</b>			
Current maturity of long term borrowings (refer note 11 )	124	131	3
Current maturity of finance lease obligation (refer note 11)	-	459	402
Current maturity of inter corporate deposit (refer note 11 )	218	4	3,079
Capital Creditors	173	4	44
	<u>515</u>	<u>598</u>	<u>3,528</u>
<b>14. Short term provision</b>			
<b>Provision for employee benefits</b>			
Provision for leave encashment	13	26	24
Provision for gratuity (refer note 24.1)	2	1	-
	<u>15</u>	<u>27</u>	<u>24</u>
<b>15. Other current liabilities</b>			
Statutory dues	39	67	103
	<u>39</u>	<u>67</u>	<u>103</u>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

(Rs in Lacs)

	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>16. Revenue from operations</b>		
Revenue from healthcare services (net)	1,348	4,161
Other operating Income		
- Sponsorship and educational income	-	45
- Income from leasing activities	877	746
<b>Total</b>	<b>2,225</b>	<b>4,952</b>
<b>17. Other income</b>		
Profit on foreign exchange fluctuation	2	-
Unclaimed Balances & excess provisions written back	39	3
Other non-operating income	2	-
	<b>43</b>	<b>3</b>
<b>18. Finance income</b>		
Interest Income on		
Bank deposits	-	3
Loans to other healthcare service providers	1,714	594
Income tax refund	14	25
	<b>1,728</b>	<b>622</b>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

	(Rs in Lacs)	
	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>19. Employee benefits expense</b>		
Salaries, wages and bonus	363	608
Contribution to provident and other funds	15	12
Gratuity expense (refer note 24.1)	9	7
Staff welfare expenses	-	3
	<u>387</u>	<u>630</u>
<b>20. Finance costs</b>		
Interest on debts and borrowings	3,661	3,075
	<u>3,661</u>	<u>3,075</u>
<b>21. Depreciation and amortization expense</b>		
Depreciation of property, plant and equipment (note 3)	513	545
Amortization of intangible assets (note 4)	13	13
	<u>526</u>	<u>558</u>
<b>22. Other expenses</b>		
Professional and consultancy fee	292	2,420
Outside lab investigations	-	590
Rent	-	11
Insurance	8	9
Rates and taxes	2	1
Facility maintenance expenses	-	12
Power and fuel	-	48
Repairs and maintenance:		
Plant and equipments	-	109
Others	1	1
Printing and stationery	-	7
Travelling and conveyance	3	62
Communication	-	4
Legal and professional	32	96
Directors' sitting fee	3	-
Net loss on sale/disposal of fixed assets	-	80
Miscellaneous expenses	1	40
	<u>342</u>	<u>3,490</u>
<b>Payment to auditor (included in legal and professional fee)</b>		
<b>As auditor:</b>		
Audit fee	10	18
Reimbursement of expenses	-	3
	<u>10</u>	<u>21</u>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**23. Commitments and contingencies**

**Leases commitment**

**Operating lease commitments - Company as lessee**

a) Vehicles are obtained on Operating lease. The lease terms are for 1 (one) year and renewable by mutual agreement of both the parties.

b) Future minimum lease payments and the payment profile of non-cancellable operating leases are as follows:

<b>Particulars</b>	<b>(Rs in Lacs)</b>		
	<b>March 31, 2017</b>	<b>March 31, 2016</b>	<b>April 1, 2015</b>
(i) not later than one year	-	11	15
(ii) later than one year and not later than five years	-	-	-
(iii) later than five years	-	-	-

**Operating lease commitments - Company as lessor**

Medical & other equipments are given on operating lease. The lease term is for initial period of 5 (five) years and renewable by mutual consent of both the parties.

<b>Particulars</b>	<b>(Rs in Lacs)</b>		
	<b>March 31, 2017</b>	<b>March 31, 2016</b>	<b>April 1, 2015</b>
Lease rent received	877	746	742

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24. Other Notes to Accounts**

**24.1 Gratuity**

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of services gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service or part thereof in excess of six months. The scheme is unfunded.

	(Rs. in Lacs)	
	Year ended March 31, 2017	Year ended March 31, 2016
<b>a) Reconciliation of opening and closing balances of Defined Benefit obligation</b>		
Defined Benefit obligation at the beginning of the year	24	24
Interest Expense	2	1
Current Service Cost	7	2
Benefit paid	(1)	-
Acquisition adjustment (Employees transferred from holding company)		
Remeasurement of (Gain)/loss in other comprehensive income		
Actuarial changes arising from changes in demographic assumptions	(5)	-
Actuarial changes arising from changes in financial assumptions	3	-
Actuarial changes arising from changes in experience adjustments	(14)	(3)
<b>Defined Benefit obligation at year end</b>	<b>16</b>	<b>24</b>
<b>b) Reconciliation of opening and closing balances of fair value of plan assets</b>		
Fair value of plan assets at beginning of the year	-	-
Expected return on plan assets	-	-
Employer contribution	-	-
Remeasurement of (Gain)/loss in other comprehensive income	-	-
Return on plan assets excluding interest income	-	-
Benefits paid	-	-
<b>Fair value of plan assets at year end</b>	<b>-</b>	<b>-</b>
<b>c) Net defined benefit asset/ (liability) recognized in the balance sheet</b>		
Fair value of plan assets	-	-
Present value of defined benefit obligation	(16)	(24)
<b>Amount recognized in Balance Sheet- Asset / (Liability)</b>	<b>(16)</b>	<b>(24)</b>
<b>d) Net defined benefit expense (Recognized in the Statement of profit and loss for the year)</b>		
Current service cost	7	6
Past service cost	-	-
Interest cost on benefit obligation	2	1
Expected return on plan assets	-	-
Net actuarial( gain) / loss recognized in the year	-	-
<b>Net defined benefit expense debited to statement of profit and loss</b>	<b>9</b>	<b>7</b>

**e) Principal assumption used in determining defined benefit obligation**

Assumption Particulars	As at March 31, 2017	As at March 31, 2016
	Discount Rate	6.60%
Salary Escalation Rate	10%	10%
Mortality Rate (% of IALM 06-08)	100%	100%

**f) Quantitative sensitivity analysis for significant assumptions is as below:**

	(Rs. in Lacs)	
	As at March 31, 2017	As at March 31, 2016
Increase / (decrease) on present value of defined benefits obligations at the end of the year		
<u>Discount rate</u>		
Increase by 1.00%	(1)	(2)
Decrease by 1.00%	1	3
<u>Salary growth rate</u>		
Increase by 1.00%	1	3
Decrease by 1.00%	(1)	(2)
<u>Attrition rate</u>		
Increase by 0.50%	(2)	(1)
Decrease by 0.50%	3	2

**g) Maturity profile of defined benefit obligation**

	(Rs. in Lacs)	
	As at March 31, 2017	As at March 31, 2016
Within the next 12 months (next annual reporting period)	2	1
Between 2 and 5 years	6	4
Between 6 and 10 years	5	9
More than 10 years	16	56
<b>Total expected payments</b>	<b>30</b>	<b>71</b>

**h)** The average duration of the defined benefit plan obligation at the end of the reporting period is 8 Years (March 31, 2016 : 12 years)

**i)** The estimates of rate of escalation in salary considered in actuarial valuation are after taking into account inflation, seniority, promotion and other relevant factors including supply and demand in the employment market. The above information is as certified by the Actuary.

**j)** Discount rate is based on the prevailing market yields of Indian Government securities as at the balance sheet date for the estimated term of the obligations.

**k)** The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.2A Fair value measurements**

Set out below, is a comparison by class of the carrying amounts and fair value of the Company's financial instruments, other than those with carrying amounts that are reasonable approximations of fair values:

Financial instruments by category	Carrying Value			Fair Value		
	March 31,2017	March 31,2016	April 1,2015	March 31,2017	March 31,2016	April 1,2015
<b>Financial assets at amortized cost</b>						
Loans	1,318	-	6,960	1,318	-	6,960
Trade receivables	195	1,277	12,068	195	1,277	12,068
Other financial assets	14,286	14,300	39	14,286	14,300	39
Cash and cash equivalents	15	27	31	15	27	31
Other bank balances	-	3	3	-	3	3
	<b>15,814</b>	<b>15,607</b>	<b>19,101</b>	<b>15,814</b>	<b>15,607</b>	<b>19,101</b>
<b>Financial Liabilities at amortized cost</b>						
Borrowings	29,170	28,161	20,216	29,170	28,161	20,216
Trade payable	356	1,064	755	356	1,064	755
Other financial liabilities	515	598	3,528	515	598	3,528
	<b>30,041</b>	<b>29,823</b>	<b>24,499</b>	<b>30,041</b>	<b>29,823</b>	<b>24,499</b>

The Company assessed that trade receivables, cash and cash equivalents, other bank balances, loans and advances to related parties, interest receivable, trade payables, capital creditors are considered to be the same as their fair values, due to their short term nature.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

Long-term fixed-rate and variable-rate receivables/borrowings are evaluated by the Company based on parameters such as interest rates, specific country risk factors, individual creditworthiness of the customer and the risk characteristics of the financed project. Based on this evaluation, allowances are taken into account for the expected credit losses of these receivables.

The fair value of unquoted instruments, loans from banks and other financial liabilities as well as other noncurrent financial liabilities are estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities. The valuation requires management to use observable and unobservable inputs in the model, of which the significant observable and unobservable inputs are disclosed in the table below. Management regularly assesses a range of reasonably possible alternatives for those significant observable and unobservable inputs and determines their impact on the total fair value.

The fair values of the Company's interest-bearing borrowings and other non-current financial liabilities are determined by using DCF method using discount rate that reflects the issuer's borrowing rate as at the end of the reporting period. The own non-performance risk as at March 31, 2017 was assessed to be insignificant.

**24.2B Fair value hierarchy**

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities

Level 2: other techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly

Level 3: techniques that use inputs that have a significant effect on the recorded fair value that are not based on observable market data

(i) Quantitative disclosure of fair value measurement hierarchy for financial assets as on March 31, 2017

Particulars	Carrying value March 31, 2017	Fair value		
		Level 1	Level 2	Level 3
Loans	1,318	-	-	1,318
Trade receivables	195	-	-	195
Other financial assets	14,286	-	-	14,286
Cash and cash equivalents	15	-	-	15

(ii) Quantitative disclosure of fair value measurement hierarchy for financial assets as on March 31, 2016

Particulars	Carrying value March 31, 2016	Fair value		
		Level 1	Level 2	Level 3
Trade receivables	1,277	-	-	1,277
Other financial assets	14,300	-	-	14,300
Cash and cash equivalents	27	-	-	27
Other bank balances	3	-	-	3

(iii) Quantitative disclosure of fair value measurement hierarchy for financial assets as on April 1, 2015

Particulars	Carrying value April 1, 2015	Fair value		
		Level 1	Level 2	Level 3
Loans	6,960	-	-	6,960
Trade receivables	12,068	-	-	12,068
Other financial assets	39	-	-	39
Cash and cash equivalents	31	-	-	31
Other bank balances	3	-	-	3

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

(iv) Quantitative disclosure of fair value measurement hierarchy for financial liabilities as on March 31, 2017

Particulars	Carrying value March 31, 2017	Fair value		
		Level 1	Level 2	Level 3
		Borrowings	29,170	-
Trade payable	356	-	-	356
Other financial liabilities)	515	-	-	515

(v) Quantitative disclosure of fair value measurement hierarchy for financial liabilities as on March 31, 2016

Particulars	Carrying value March 31, 2016	Fair value		
		Level 1	Level 2	Level 3
		Borrowings	28,161	-
Trade payable	1,064	-	-	1,064
Other financial liabilities)	598	-	-	598

(vi) Quantitative disclosure of fair value measurement hierarchy for financial liabilities as on April 1, 2015

Particulars	Carrying value April 1, 2015	Fair value		
		Level 1	Level 2	Level 3
		Borrowings	20,216	-
Trade payable	755	-	-	755
Other financial liabilities)	3,528	-	-	3,528

**24.3 Earnings per share (EPS)**

Particulars	(Rs. in Lacs)	
	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>A) Basic Earnings per share</b>		
Numerator for earnings per share :-		
Loss after taxation	(923)	(2,253)
Denominator for earnings per share :-		
Weighted number of equity shares outstanding during the year	29,146,700	29,146,700
Earnings per share-Basic (one equity share of Re. 10/- each)	(3.17)	(7.73)
<b>B) Diluted Earnings per share</b>		
Numerator for earnings per share :-		
Loss after taxation	(923)	(2,253)
Denominator for earnings per share :-		
Weighted number of equity shares outstanding during the year	29,646,700	29,146,700
Earnings per share- Diluted (one equity share of Re. 10/- each)*	(3.11)	(7.73)

\* The conversion effect of potential preference shares into equity shares is anti-dilutive in nature, hence the effect of potential equity shares are ignored in calculating dilutive earning per share.

**24.4 Capital Management**

For the purpose of the Company's capital management, capital includes issued equity attributable to the equity shareholders of the Company, share premium and all other equity reserves. The primary objective of the Company's capital management is that it maintain an efficient capital structure and maximize the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, The Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, less cash and cash equivalents, excluding discontinued operations.

Particulars	(Rs. in Lacs)		
	As At March 31, 2017	As At March 31, 2016	As At April 1, 2015
Borrowings (refer note 11)	29,512	28,755	23,700
Less: cash and cash equivalents (refer note 8)	(15)	(27)	(31)
<b>Net debt</b>	<b>29,497</b>	<b>28,728</b>	<b>23,669</b>
Equity (refer note 10)	(1,605)	(1,698)	552
<b>Total capital</b>	<b>(1,605)</b>	<b>(1,698)</b>	<b>552</b>
<b>Total capital and Net debt</b>	<b>27,892</b>	<b>27,030</b>	<b>24,221</b>
Gearing Ratio	106%	106%	98%

**24.5 Deferred Tax Asset/ (Liability)**

The Company follows Ind AS 12 "Accounting for Income Taxes", as notified by Companies Indian Accounting Standards Rules, 2015. Due to losses, the company has deferred tax asset with loss and unabsorbed depreciation as a major component. However, deferred tax asset has been considered nil and has been recognized only to the extent of deferred tax liability since there is no convincing evidence which demonstrates virtual certainty of realization of such deferred tax asset in the near future, accordingly Company has prudently decided not to recognize deferred tax asset on such timing differences.



#### 24.6 Financial risk management objectives and policies

The Company's has instituted an overall risk management programme which also focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company's financial performance. The Company uses forward covers to hedge foreign currency risk exposures. Financial risk management is carried out by a Corporate Finance department under policies approved by the audit committee from time to time. The Corporate Finance department, evaluates and hedges financial risks in close co-operation with the various stakeholders. The audit committee approves written principles for overall financial risk management, as well as written policies covering specific areas, such as foreign exchange risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

The Company is exposed to capital risk, market risk, credit risk and liquidity risk. These risks are managed pro-actively by the Senior Management of the Company, duly supported by various Groups and Committees.

##### a) Capital Risk

The Company's objective when managing capital is to safeguard its ability to continue as a going concern in order to provide returns to its shareholders and benefits for other stakeholders and to provide for sufficient capital expansion. The capital structure of the Company consists of debt, which includes the borrowings disclosed in notes 11 and 13, cash and cash equivalents disclosed in note 8 and equity as disclosed in the statement of financial position. The Company uses the Debt : Equity as well as Net Debt to EBITDA ratio to measure the funding versus raising of additional share capital requirement. The ratio is calculated as Net debt divided by the Shareholder's Fund for Debt : Equity and for Net Debt to EBITDA, Net Debt is divided by the Normalized EBITDA for 12 months. Net debt is calculated as total interest-bearing borrowings (including "current interest-bearing and non-current interest-bearing borrowings" as shown in the statement of financial position) less net cash and cash equivalents. Normalized EBITDA is defined as earnings before interest, tax, depreciation and amortization, adjusted for non-operating items, one offs and for any mid of the year merger and acquisition activity. In order to maintain or adjust the capital structure, the Company may issue new shares or sell assets to reduce debt or raise debt and review decision on distributions to the shareholders. The Debt : Equity ratio of the Company stood at (16.12) for FY15-16 and (18.19) for FY 2016-17. Similarly, the Net Debt to EBITDA ratio of the Company stood at 19.84 for FY 2015-16 and 8.94 FY 2016-17.

Note : Working capital facility amount is not included in interest rate borrowing amount and in Debt for computation of Debt Equity ratio

##### b) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company employees prudent liquidity risk management practices which inter alia means maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities. Given the nature of the underlying businesses, the corporate finance maintains flexibility in funding by maintaining availability under committed credit lines and this way liquidity risk is mitigated by the availability of funds to cover future commitments. Cash flow forecasts are prepared not only for the entities but the Group as a whole and the utilized borrowing facilities are monitored on a daily basis and there is adequate focus on good management practices whereby the collections are managed efficiently. The Company while borrowing funds for large capital project, negotiates the repayment schedule in such a manner that these match with the generation of cash on such investment. Longer term cash flow forecasts are updated from time to time.

The table below represents the maturity profile of Company's financial liabilities at the end of April 1, 2015, March 31, 2016 and March 31, 2017 based on contractual undiscounted payments :-

(Rs. in Lacs)				
April 1, 2015	0-1 Years	1-5 Years	More than 5 Years	Total
Interest bearing borrowings	21,194	2,506	-	23,700
Trade payable	755	-	-	755
Other financial liabilities	44	-	-	44
<b>% to Total</b>	<b>90%</b>	<b>10%</b>	<b>0%</b>	<b>100%</b>
March 31, 2016				
Interest bearing borrowings	2,257	4,813	20,620	27,690
Trade payable	1,064	-	-	1,064
Other financial liabilities	4	-	-	4
<b>% to Total</b>	<b>12%</b>	<b>17%</b>	<b>72%</b>	<b>100%</b>
March 31, 2017				
Interest bearing borrowings	342	4,031	25,108	29,481
Trade payable	356	-	-	356
Other financial liabilities	173	-	-	173
<b>% to Total</b>	<b>3%</b>	<b>13%</b>	<b>84%</b>	<b>100%</b>

##### c) Credit Risk

Credit Risk is the risk that the counter party will not meet its obligation under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

##### (i) Trade receivables

Customer credit risk is managed by each business unit subject to the Company's established policy, procedures and control relating to customer credit risk management. Management evaluate credit risk relating to customers on an ongoing basis. Receivable control management Department assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Trade receivables is mainly form Gujarmal Modi Hospital & Research centre for Medical Sciences.

(Rs. in Lacs)			
Trade receivables	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Neither past due or impaired	195	774	10,051
0 to 180 days due past due date	-	503	1,710
More than 180 days due past due date	-	-	307
<b>Total trade receivables</b>	<b>195</b>	<b>1,277</b>	<b>12,068</b>

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**(ii) Financial instruments and cash deposit**

Credit risk from balances with banks and financial institutions is managed by the Company's treasury department in accordance with the Company's policy. Investments of surplus funds are made in bank deposits and other risk free securities. The limits are set to minimize the concentration of risks and therefore mitigate financial loss through counter party's potential failure to make payments. Credit limits of all authorities are reviewed by the management on regular basis. All balances with banks and financial institutions is subject to low credit risk due to good credit ratings assigned to the Company.

The Company's maximum exposure to credit risk for the components of the balance sheet at March 31, 2017, March 31, 2016 and April 1, 2015 is the carrying amounts as illustrated in note 24.2 A and the liquidity table above.

**d) Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprises three types of risk: currency rate risk, interest rate risk and other price risks, such as equity price risk and commodity price risk. Financial instruments affected by market risks include loans and borrowings, deposits, investments and foreign currency receivables and payables. The sensitivity analyses in the following sections relate to the position as at March 31 2017. The analyses exclude the impact of movements in market variables on; the carrying values of gratuity and other post-retirement obligations; provisions; and the non-financial assets and liabilities. The sensitivity of the relevant Profit and Loss item is the effect of the assumed changes in the respective market risks. This is based on the financial assets and financial liabilities held as of March 31, 2017.

**(i) Foreign Currency Risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in foreign currency). Foreign currency exchange rate exposure is partly balanced by purchasing of goods from the respective countries. The Company evaluates exchange rate exposure arising from foreign currency transactions and follows established risk management policies.

Foreign currency risk sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant. The impact on the company profit before tax is due to changes in the fair value of monetary assets and liabilities.

Unhedged foreign currency exposures recognized by the Company are as under:

(Rs. in Lacs)					
Currency	As at	Amount in Foreign Currency	Amount in India Rupee	Increase/decrease in rate	Impact on profit before tax
In USD	March 31, 2017	1	39	1%	0.39
In USD	March 31, 2016	-	-	1%	-
In USD	April 1, 2015	-	-	1%	-

**(ii) Interest Rate Risk**

Interest rate is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long term debt obligation at floating interest rates. The Company's policy is to hedge part of its borrowings.

Interest rate Sensitivity of Borrowings

With all other variables held constant, the following table demonstrates the sensitivity to a reasonably possible change in interest rates on floating rate portion of loans and borrowings.

(Rs. in Lacs)		
Year	Increase/decrease in Interest rate	Effect on profit before tax
March 31,2017	0.50%	121
March 31,2016	0.50%	42
April 1,2015	0.50%	-

**24.7 Related party transactions**

The related parties as per the terms of Ind AS-24,"Related Party Disclosures", ( specified under section 133 of the Companies Act, 2013, read with Rule 7 of Companies (Accounts) Rules, 2015 ) are disclosed below:-

**(A) Names of related parties and description of relationship :**

**Related party where control exists**

**(i) Holding Companies**

- 1) Max Healthcare Institute Limited (w.e.f December 1, 2015)
- 2) Smart Health City Pte. Ltd., Singapore (till November 30, 2015)

**(ii) Fellow Subsidiaries**

- 1) Hometrail Estate Private Limited (w.e.f December 1, 2015)
- 2) Hometrail Buildtech Private Limited (w.e.f December 1, 2015)
- 3) Max Medical Services Limited (w.e.f December 1, 2015)
- 4) Alps Hospital Limited (w.e.f December 1, 2015)
- 5) Crosslay Remedies Limited (w.e.f December 1, 2015)

**(iii) Key Management Personnel**

- 1) Dr. Bhupendra Kumar Modi (Chairman)
- 2) Mr. Rajit Mehta (Vice Chairman)
- 3) Mr. Soubir Ghosh (Head of finance - Manager ) (As per Companies Act, 2013)
- 4) Ms. Poonam Makkar (Company Secretary) (As per Companies Act, 2013)

**(iv) Enterprises owned or significantly influenced by key management personnel**

- 1) Gujarmal Modi Hospital & Research Centre for Medical Sciences (till November 27, 2015)
- 2) Smart Value Ventures Private Limited (till November 27, 2015)

Saket City Hospitals Private Limited  
Notes forming part of the financial statements

(Rs. in Lacs)

(B) Transaction during the year	For the year ended March 31, 2017	For the year ended March 31, 2016
<b>Unsecured Borrowings :-</b>		
Max Healthcare Institute Limited (Holding Company)	1,900	200
<b>Unsecured borrowings repaid</b>		
Smart Value Ventures Pvt. Ltd.	-	17,003
<b>Revenue from Operating Lease</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	746
<b>Income from Healthcare Services</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	4,188
<b>Interest Income</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	594
<b>Interest on Loans :-</b>		
Max Healthcare Institute Limited (Holding Company)	214	4
Smart Value Ventures Pvt. Ltd.		1,370
<b>Loan refund recived:-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences		8,159
<b>Sale of fixed assets:-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences		20
<b>Loan given:-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences		1,199
<b>Security deposit paid :-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences		21,429
<b>Finance Cost :-</b>		
Max Healthcare Institute Limited (Holding Company)	134	44
<b>Preference Shares :-</b>		
Max Healthcare Institute Limited (Holding Company)	1,000	-
<b>Salary:-</b>		
Ms. Anamika Sikri	-	48
Mr. Kamalapati Kashyap	-	8
Dr. Ashok Vardhan Chordiya	-	87
Mr Soubir Ghosh	19	-
Ms Poonam Makkar	9	-

(Rs. in Lacs)

(C) Balance outstanding at the year end	As at March 31, 2017	As at March 31, 2016
<b>Unsecured Borrowings :-</b>		
Max Healthcare Institute Limited (Holding Company)	2,318	204
<b>Equity share capital :-</b>		
Max Healthcare Institute Limited (Holding Company)	32,500	32,500
<b>Preference shares :-</b>		
Max Healthcare Institute Limited (Holding Company)	1,000	-
<b>Trade receivable :-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	1,277
<b>Security deposit :-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	21,429
<b>Accrued income :-</b>		
Gujarmal Modi Hospital & Research Centre For Medical Sciences	-	14
<b>Other Payable</b>		
Max Healthcare Institute Limited (Holding Company)	200	46

24.8 Segment reporting

The Company operates into two major segments: leasing and other than leasing. Information by each reportable segment is as follows:

S. No.	Particulars	Segment		Total
		Leasing	Other than Leasing	
1	External Sales	-	-	-
2	Revenue from operation	877	1,348	2,225
		(746)	(4,206)	(4,952)
3	Segment Expenses	369	542	911
		(399)	(3,468)	(3,867)
4	Segment Result	508	806	1,314
		(347)	(738)	(1,085)
5	Unallocated Expenses			190
				(729)
6	Unallocated Incomes			43
				(3)
7	Interest Incomes			1,728
				(622)
8	Operating profit			2,895
				(981)
9	Depreciation and Amortisation			157
				(159)
10	Operating Profit after depreciation			2,738
				(822)
11	Financial Expenses			3,661
				(3,075)
12	Loss before tax			(923)
				((2253))
13	Tax Expense			-
				-
14	Loss after Tax			(923)
				((2253))
	Other Informations :-			
15	Segment Assets	3,291	1,386	4,677
		(3,137)	(3,212)	(6,349)
16	Unallocated Assets			23,827
				(21,893)
17	Total Assets			28,504
				(28,242)
18	Segment Liabilities	10	92	102
		(13)	(893)	(906)
19	Unallocated Liabilities			30,007
				(29,034)
	Total Liabilities			30,109
				(29,940)

(figures in bracket represents previous year) / (figures in double bracket represents loss of previous year)

The Company operates in single geographical Segment.

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.9A Reconciliation statement of equity as previously reported under IGAAP to Ind AS**

(Rs in Lacs)

	Footnotes	Balance sheet as at April 1, 2015		
		IGAAP	Adjustment	Ind AS
<b>ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and equipment		5,515	-	5,515
Intangible assets		54	-	54
Financial assets				
Loans		6,612	-	6,612
Trade receivables		7,993	-	7,993
		<b>20,174</b>	<b>-</b>	<b>20,174</b>
<b>Current assets</b>				
Inventories		7	-	7
Financial assets				
Loans		348	-	348
Trade receivables		4,075	-	4,075
Other financial assets		39	-	39
Cash and cash equivalents		31	-	31
Other bank balances		3	-	3
Other current assets		521	-	521
		<b>5,024</b>	<b>-</b>	<b>5,024</b>
<b>TOTAL ASSETS</b>		<b>25,198</b>	<b>-</b>	<b>25,198</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Equity share capital		2,915	-	2,915
Other equity		(2,363)	-	(2,363)
<b>Total Equity</b>		<b>552</b>	<b>-</b>	<b>552</b>
<b>Non-current liabilities</b>				
Financial Liabilities				
Borrowings		20,216	-	20,216
Long term provisions		20	-	20
		<b>20,236</b>	<b>-</b>	<b>20,236</b>
<b>Current liabilities</b>				
Financial Liabilities				
Trade payables		755	-	755
Other financial liabilities		3,528	-	3,528
Short term provisions		24	-	24
Other current liabilities		103	-	103
		<b>4,410</b>	<b>-</b>	<b>4,410</b>
<b>TOTAL LIABILITIES</b>		<b>24,646</b>	<b>-</b>	<b>24,646</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>25,198</b>	<b>-</b>	<b>25,198</b>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.9B Reconciliation statement of equity as previously reported under IGAAP to Ind AS**

(Rs in Lacs)				
	Footnotes	Balance sheet as at March 31,2016		
		IGAAP	Adjustment	Ind AS
<b>ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and equipment	1	4,892	-	4,892
Intangible assets	1	41	-	41
Financial assets				
Other financial assets	2	21,428	(7,142)	14,286
Other non current assets	2	-	7,036	7,036
		<b>26,361</b>	<b>(106)</b>	<b>26,255</b>
<b>Current assets</b>				
Inventories		3	-	3
Financial assets				
Trade receivables		1,277	-	1,277
Other financial assets		14	-	14
Cash and cash equivalents		27	-	27
Other bank balances		3	-	3
Other current assets	2	518	145	663
		<b>1,842</b>	<b>145</b>	<b>1,987</b>
<b>TOTAL ASSETS</b>		<b>28,203</b>	<b>39</b>	<b>28,242</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Equity share capital		2,915	-	2,915
Other equity	5	(4,935)	322	(4,613)
<b>Total Equity</b>		<b>(2,020)</b>	<b>322</b>	<b>(1,698)</b>
<b>Non-current liabilities</b>				
Financial Liabilities				
Borrowings	3	27,095	(283)	26,812
Long term provisions		23	-	23
		<b>27,118</b>	<b>(283)</b>	<b>26,835</b>
<b>Current liabilities</b>				
Financial Liabilities				
Borrowings		1,349	-	1,349
Trade payables		1,064	-	1,064
Other financial liabilities		598	-	598
Short term provisions		27	-	27
Other current liabilities		67	-	67
		<b>3,105</b>	<b>-</b>	<b>3,105</b>
<b>TOTAL LIABILITIES</b>		<b>30,223</b>	<b>(283)</b>	<b>29,940</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>28,203</b>	<b>39</b>	<b>28,242</b>

[This space has been intentionally left blank]

Saket City Hospitals Private Limited  
Notes forming part of the financial statements

24.9C Reconciliation statement of profit and loss as previously reported under IGAAP to Ind AS

	Footnotes	(Rs. in Laacs)		
		Year ended March 31, 2016		
		IGAAP	Adjustment	Ind AS
<b>INCOME</b>				
Revenue from operations	2	4,979	(27)	4,952
Other income		3	-	3
Finance income		622	-	622
<b>Total income</b>		<b>5,604</b>	<b>(27)</b>	<b>5,577</b>
<b>Expenses</b>				
Purchase of pharmacy, drugs, consumables and implants		77	-	77
(Increase)/decrease in inventory of pharmacy, drugs and consumables and implants		-	-	-
Employee benefits expense	4,6	627	3	630
Finance costs	3	3,424	(349)	3,075
Depreciation and amortization expense		558	-	558
Other expenses		3,490	-	3,490
<b>Total expense</b>		<b>8,176</b>	<b>(346)</b>	<b>7,830</b>
Loss before tax		(2,572)	319	(2,253)
Tax expenses		-	-	-
<b>Loss for the year</b>		<b>(2,572)</b>	<b>319</b>	<b>(2,253)</b>
<b>Other comprehensive income</b>				
Other comprehensive income not to be reclassified to profit or loss in subsequent periods:				
Re-measurement losses on defined benefit plans	4,6	-	3	3
Income tax effect		-	-	-
Other comprehensive income for the year, net of tax		-	3	3
<b>Total comprehensive income for the year, net of tax attributable to Equity shareholder</b>		<b>(2,572)</b>	<b>322</b>	<b>(2,250)</b>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.9D Footnotes to the reconciliation of equity as at April 1, 2015 and March 31, 2016 and profit or loss for the year ended March 31, 2016**

**1) Property, plant and equipment**

The Company has elected to apply the exemption available under Ind AS -101 to continue the carrying value for all of its property, plant and equipment and intangibles as recognized in the financial statement as at the date of transition to Ind AS, measured as per the previous GAAP and use that as its deemed cost as at the date of transition (April 1, 2015). However, to restate the carrying amount of borrowings in accordance in the paragraph 10 of Ind AS-101, carrying amount of fixed assets as at the date of transition has been reduced by the amount of processing cost and impact of fair valuation of loan (net of cumulative depreciation impact).

**2) Security deposits**

Under the previous GAAP, interest free security deposits (that are refundable in cash on completion of the lease term) are recorded at their transaction value. Under Ind AS, all financial assets are required to be recognized at fair value. Accordingly, the company has fair valued these security deposits under Ind AS. Difference between the fair value and transaction value of the security deposit has been recognized as prepaid expenses. Amortization of prepaid expenses has been adjusted against revenue from healthcare services which is partially set off with notional interest income in statement of profit & loss.

**3) Borrowings**

Ind AS 109 requires transaction costs incurred towards origination of borrowings to be deducted from the carrying amount of borrowings on initial recognition. These costs are recognized in the profit or loss over the tenure of borrowing as part of the interest expense applying the effective interest rate method. Under previous GAAP, these transaction costs were charged to profit or loss as and when incurred. Accordingly, finance cost for the year ending have been increased with a corresponding adjustment to borrowing.

**4) Remeasurements of post-employment benefit obligations**

Both under previous GAAP and Ind AS, the Company recognized costs related to its post employment defined benefit plan on an actuarial basis. Under Indian GAAP, the entire cost, including actuarial gains and losses, are charged to profit or loss. Under Ind AS, measurements (comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets excluding amounts included in net interest on the net defined liability) are recognized in balance sheet through other comprehensive income.

**5) Retained earnings**

Retained earnings as at April 1, 2015 and March 31, 2016 has been adjusted consequent to the Ind AS transition adjustments mentioned herewith.

**6) Other comprehensive Income**

Under Ind AS, all items of income and expense recognised in a period should be included in profit or loss for the period, unless a standard requires or permits otherwise. Items of income and expense that are not recognised in profit or loss but are shown in the statement of profit and loss as 'other comprehensive income' and includes remeasurement of defined benefit plans. The concept of other comprehensive income did not exist under Indian GAAP.

**7) Statement of cash flows**

The transition from Indian GAAP to Ind AS has not had a material impact on the statement of cash flows.

[This space has been intentionally left blank]



**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.10 First-time adoption of Ind AS (Exception and exemption availed)**

These financial statements, for the year ended March 31, 2017, are the first financial statements which have been prepared in accordance with Ind AS notified under the Companies Indian Accounting Standard Rules, 2015.

Accordingly, the Company has prepared financial statements which comply with Ind AS applicable for year ended on March 31, 2017, together with the comparative period data as at and for the year ended March 31, 2016, as described in the summary of significant accounting policies. In preparing these financial statements, the Company's opening balance sheet was prepared as at April 1, 2015, the Company's date of transition to Ind AS. This note explains the principal adjustments made by the Company in restating its Indian GAAP financial statements, including the balance sheet as at April 1, 2015 and the financial statements as at and for the year ended March 31, 2016.

**Ind-AS optional exemption**

Ind AS 101 allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has applied the following exemptions:

**Deemed cost**

Ind AS 101 permits a first time adopter to elect to fair value of its property, plant and equipment as recognized in financial statements as at the date of transition to Ind AS, measured as per previous GAAP and use that as its deemed cost as at the date of transition or apply principles of Ind AS retrospectively. Ind AS 101 also permits the first time adopter to elect to continue with the carrying value for all of its property, plant and equipment as recognized in the financial statements as at the date of transition to Ind AS. This exemption can be also used for intangible assets covered by Ind-AS 38.

The Company has elected to consider carrying value of its property, plant and equipment as its deemed cost on the date of transition to Ind AS.

**Ind AS mandatory exceptions**

**Estimates**

An entity estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error. Ind AS estimates at April 1, 2015 are consistent with the estimates as at the same date made in conformity with previous GAAP.

**Derecognition of financial assets and financial liabilities**

Ind AS 101 requires a first time adopter to apply the derecognition provisions of Ind AS 109 prospectively for transactions occurring on or after the date of transition to Ind AS. Accordingly, the Company has applied the derecognition requirement for financial assets and financial liabilities in Ind AS 109 prospectively for transactions occurring on or after date of transition to Ind AS.

**Classification of financial assets and liabilities**

Ind AS 101 requires an entity to assess classification and measurement of financial assets on the basis of facts and circumstances that exist on the date of transition to Ind AS. Accordingly, the Company has applied the above requirement prospectively.

**Impairment of financial assets**

Ind AS 101 requires an entity to assess and determine the impairment allowance on financial assets as per Ind AS 109 using the reasonable and supportable information that is available without undue cost or effort to determine the credit risk at the date that financial instruments were initially recognized and compare it to the credit risk at the date of transition to Ind AS. The Company has applied this exception prospectively.

**Fair value measurement of financial assets or financial liabilities (Ind AS 101.D20)**

First-time adopters may apply Ind AS 109 to day one gain or loss provisions prospectively to transactions occurring on or after the date of transition to Ind AS. Therefore, unless a first-time adopter elects to apply Ind AS 109 retrospectively to day one gain or loss transactions, transactions that occurred prior to the date of transition to Ind AS do not need to be retrospectively restated.

**24.11** Pursuant to notification of Ministry of Corporate Affairs dated March 30, 2017, disclosure of specified bank notes (SBN) held and transacted during the period from November 08, 2016 to December 30, 2016 is provided in table below:

	(In absolute Rupees)		
	SBNs	Other denomination notes	Total
<b>Closing cash in hand as on 08.11.2016</b>	<b>4,000</b>	<b>346</b>	<b>4,346</b>
+ Permitted Receipts	-	-	-
(-) Permitted Payments	-	-	-
Amount Deposited in Banks	4,000	-	4,000
<b>Closing cash in hand as on 30.12.2016</b>	<b>-</b>	<b>346</b>	<b>346</b>

[This space has been intentionally left blank]

**Saket City Hospitals Private Limited**  
**Notes forming part of the financial statements**

**24.12** The figures have been rounded off to the nearest Lacs of rupees up to two decimal places. The figure 0.00 wherever stated represents value less than Rs. 50,000/-.

**24.13** Note No.1 to 24 form integral part of the balance sheet and statement of profit and loss.

**As per our report of even date**

**For S.R. Batliboi & Co. LLP**  
**Chartered Accountants**  
**ICAI Firm Registration Number: 301003E/E300005**

**For and on behalf of the Board of Directors of**  
**Saket City Hospitals Private Limited**

**Sd/-**  
**per Atul Seksaria**  
Partner  
Membership Number: 086370

**Sd/-**  
**Yogesh Kumar Sareen**  
(Director)  
DIN:00884252

**Sd/-**  
**Kamalpati Kashyap**  
(Director)  
DIN:02359002

**Sd/-**  
**Soubir Ghosh**  
(Head of Finance)

**Sd/-**  
**Poonam Makkar**  
(Company Secretary)  
Membership No. FCS-7919

Place : Gurgaon  
Date : May 17, 2017

Place : Gurgaon  
Date : May 17, 2017